Business Context and Reporting Period
This Form 8-K Current Report was filed by Organogenesis Holdings Inc. on November 19, 2021. The filing addresses corporate governance changes, specifically the appointment of a new independent director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and regulatory compliance rather than financial performance.
Material Changes
- Board Appointment: Prathyusha Duraibabu was appointed as an independent director effective November 19, 2021, bringing the total number of board members to eight.
- Committee Assignment: Ms. Duraibabu was appointed to the Audit Committee.
- Regulatory Compliance: The appointment restored the company's compliance with Nasdaq Listing Rule 5605(c)(2)(A), which mandates that the Audit Committee consist of at least three independent directors. This resolved a prior non-compliance issue within the Nasdaq cure period.
Guidance, Outlook, and Compensation
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. Regarding compensation for the new director:
- Cash Compensation: Ms. Duraibabu will receive standard cash compensation, including retainer fees for board and committee service.
- Equity Award: She received an award of 11,340 restricted stock units (RSUs). These units vest in equal annual installments over three years, with each unit representing the right to receive one share of Class A common stock upon vesting.
- Agreements: She is covered by the company's standard indemnification and change in control retention agreements.
Investor Verification Checklist
- Verify the current composition of the Board of Directors and Audit Committee to confirm the three independent director requirement is met.
- Review the press release (Exhibit 99.1) for additional biographical details on Prathyusha Duraibabu.
- Check subsequent filings for any changes to the vesting schedule or compensation structure of the awarded RSUs.
- Confirm the company's ongoing compliance status with Nasdaq listing standards in future reports.